ABSTRACT
Doxazosin, a quinazoline derivative, is a selective alpha 1-inhibitor that reduces calculated coronary heart disease risk by lowering blood pressure while favorably affecting blood lipid levels. The aim of this study was to cases efficacy and safety of Daxazosin in patients with mild to dolerite essential hypertension. This was an open non-comparative study. The study subjective were 31 patients with essential hypertension. The study involved 2 weeks baseline period followed by 10 weeks titration/maintenance period in which patients received Doxazosin 1mg to once daily. Mean blood pressure of 31 patients was 152 mm H[g] systolic and 98 mm H[g] diastolic at baseline. After to weeks of Doxazosin therapy, the mean systolic and diastolic blood pressure dropped to 135 mmH[g] and 82 mmH[g] respectively. The mean reduction in systolic and diastolic blood pressure was 17 mmH[g] and 16 mmH[g] respectively. These reductions were found to be statistically significant. This confirms the established antihypertensive affect due to vasodilatation. At baseline the mean values for total cholesterol was 192.2 mg/dl, for HDL-c 41.2 mg/dl, for LDL-c 105.1 mg/dl, and for triglyceides was 257.2 mg/dl. At the end of the study the mean values for total cholesterol was 179.1 mg/dl, for HDL-c was 40.6mg/dl, for DL-c 106.7 mg/dl and for triglycerides was 192.2 mg/dl. Thus doxazosin produced a favorable but statiscally insignificant [P> 0.05] effect on lipid parameters. No patient required dose reduction or discontinuation of therapy because of side effects. The global assessment of efficacy of once daily Doxazosin therapy was excellent for 24[77.4%] patients and good in 7[22.6%] patients. The overall assessment of toleration as assessed by the investigator was excellent in 29[93.5%] patients and good in 2[6.5%] patients. it is concluded that Doxazosin is a well-tolerated and effective antihypertensive drug with a favorable effect on blood lipids. Doxazosin provides an alternative first ling drug for the treatment of mild to moderature essential hypertension